Nephrostomies in obstructive uropathy; how should hormone resistant prostate cancer patients be managed and can we predict who will benefit?

被引：0
|
作者：
M R E Harris
M J Speakman
机构：
[1] Taunton and Somerset NHS Trust,
[2] Musgrove Park Hospital,undefined
来源：
Prostate Cancer and Prostatic Diseases | 2006年 / 9卷
关键词：
nephrostomy; hormone; obstructive uropathy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Current opinion advocates the use of nephrostomies in hormone naive patients with obstructive uropathy while hormone resistant patients require an individual approach. Patients undergoing a nephrostomy for uropathy were retrospectively analysed, with particular interest in hormone status and blood levels. Over a 46-month period, 26/112 nephrostomies were performed for prostate cancer induced uropathy. Survival was 226.5 days for hormone naive patients, 114.3 days in the responsive group and 100.2 days if resistant. Bilateral cases survived 72.1 days versus 157.6 days for unilateral patients. All patients should be considered for nephrostomy despite their hormone status.
引用
收藏
页码：42 / 44
页数：2
相关论文
共 50 条
  • [21] OBSTRUCTIVE SLEEP APNEA IN NON-IPF FIBROTIC ILD PATIENTS: WHO, HOW AND WHAT SHOULD WE OFFER?
    Gouveia Cardoso, C.
    Valente, C.
    Serino, M.
    Rodrigues, I.
    Carvalho, A.
    Santos, R.
    Coelho, D.
    Terras Alexandre, A.
    Melo, N.
    Novais Bastos, H.
    Caetano Mota, P.
    Morais, A.
    Drummond, M.
    SLEEP MEDICINE, 2024, 115 : 256 - 256
  • [22] How can we predict permanent xerostomia after radiotherapy in patients with head and neck cancer?
    Bruvo, M.
    Pedersen, A. M. L.
    Samsoe, E.
    Maare, C.
    Mahmood, F.
    RADIOTHERAPY AND ONCOLOGY, 2021, 161 : S373 - S375
  • [23] How Can We Predict Who Would Benefit From a Small-Bowel Capsule Endoscopy When Staging Crohn Disease?
    Robertson, Alexander R.
    Arnott, Ian D.
    INFLAMMATORY BOWEL DISEASES, 2021, 27 (06) : E67 - E68
  • [24] Are There Still Patients with Metastatic Hormone-sensitive Prostate Cancer Who Should Be Treated with Androgen Deprivation Monotherapy?
    Kretschmer, Alexander
    Todenhoefer, Tilman
    EUROPEAN UROLOGY FOCUS, 2019, 5 (02): : 114 - 116
  • [25] The genetic basis of response to checkpoint inhibitors Why do some patients respond and how can we predict who will?
    Kotoula, Vassiliki
    MEDICINE, 2019, 98 (26)
  • [26] The prognostic factors of effective ketoconazole treatment for metastatic castration-resistant prostate cancer: who can benefit from ketoconazole therapy?
    Lin, Guo-Wen
    Yao, Xu-Dong
    Ye, Ding-Wei
    Zhu, Yao
    Zhang, Shi-Lin
    Dai, Bo
    Zhang, Hai-Liang
    Shen, Yi-Jun
    Ma, Chun-Guang
    ASIAN JOURNAL OF ANDROLOGY, 2012, 14 (05) : 732 - 737
  • [27] Should We Try Antiandrogen Withdrawal in Castration-Resistant Prostate Cancer Patients? Insights From a Retrospective Study
    Hongo, Hiroshi
    Kosaka, Takeo
    Mizuno, Ryuichi
    Ezaki, Taisuke
    Matsumoto, Kazuhiro
    Morita, Shinya
    Shinoda, Kazunobu
    Shinojima, Toshiaki
    Kikuchi, Eiji
    Miyajima, Akira
    Oya, Mototsugu
    CLINICAL GENITOURINARY CANCER, 2016, 14 (06) : E569 - E573
  • [28] The management of category T1a-T1b (incidental) prostate cancer: Can we predict who needs treatment?
    Adolfsson, Jan
    EUROPEAN UROLOGY, 2008, 54 (01) : 16 - 18
  • [29] HOW CAN WE IMPROVE THE DESIGN OF PATIENT PREFERENCE RESEARCH IN ONCOLOGY? A CASE STUDY IN METASTATIC CASTRATE RESISTANT PROSTATE CANCER
    Dearden, L.
    Eliasson, L.
    de Freitas, H.
    Shalet, N.
    Lloyd, A.
    VALUE IN HEALTH, 2015, 18 (07) : A472 - A473
  • [30] HOW SHOULD WE MANAGE PATIENTS WITH LOCOREGIONALLY ADVANCED HEAD AND NECK CANCER WHO ARE NOT SUITABLE FOR CHEMO-RADIOTHERAPY
    O'Sullivan, B.
    RADIOTHERAPY AND ONCOLOGY, 2011, 99 : S24 - S24
12345